Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.
Journal
NPJ systems biology and applications
ISSN: 2056-7189
Titre abrégé: NPJ Syst Biol Appl
Pays: England
ID NLM: 101677786
Informations de publication
Date de publication:
18 Aug 2024
18 Aug 2024
Historique:
received:
23
11
2023
accepted:
07
08
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
18
8
2024
Statut:
epublish
Résumé
Glioblastoma is the most common and deadliest brain tumour in adults, with a median survival of 15 months under the current standard of care. Immunotherapies like immune checkpoint inhibitors and oncolytic viruses have been extensively studied to improve this endpoint. However, most thus far have failed. To improve the efficacy of immunotherapies to treat glioblastoma, new single-cell imaging modalities like imaging mass cytometry can be leveraged and integrated with computational models. This enables a better understanding of the tumour microenvironment and its role in treatment success or failure in this hard-to-treat tumour. Here, we implemented an agent-based model that allows for spatial predictions of combination chemotherapy, oncolytic virus, and immune checkpoint inhibitors against glioblastoma. We initialised our model with patient imaging mass cytometry data to predict patient-specific responses and found that oncolytic viruses drive combination treatment responses determined by intratumoral cell density. We found that tumours with higher tumour cell density responded better to treatment. When fixing the number of cancer cells, treatment efficacy was shown to be a function of CD4 + T cell and, to a lesser extent, of macrophage counts. Critically, our simulations show that care must be put into the integration of spatial data and agent-based models to effectively capture intratumoral dynamics. Together, this study emphasizes the use of predictive spatial modelling to better understand cancer immunotherapy treatment dynamics, while highlighting key factors to consider during model design and implementation.
Identifiants
pubmed: 39155294
doi: 10.1038/s41540-024-00419-4
pii: 10.1038/s41540-024-00419-4
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Subventions
Organisme : Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada)
ID : RGPIN-2018-04546
Informations de copyright
© 2024. The Author(s).
Références
Wirsching, H.-G. & Weller, M. Glioblastoma. In Malignant Brain Tumors: State-of-the-Art Treatment (eds. Moliterno Gunel, J. et al.) 265–288 (Springer International Publishing, Cham, 2017).
Stupp, R. et al. Radiotherapy plus Concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352, 987–996 (2005).
pubmed: 15758009
doi: 10.1056/NEJMoa043330
Madani, F., Esnaashari, S. S., Webster, T. J., Khosravani, M. & Adabi, M. Polymeric nanoparticles for drug delivery in glioblastoma: state of the art and future perspectives. J. Controlled Release 349, 649–661 (2022).
doi: 10.1016/j.jconrel.2022.07.023
Delgado-López, P. D. & Corrales-García, E. M. Survival in glioblastoma: a review on the impact of treatment modalities. Clin. Transl. Oncol. 18, 1062–1071 (2016).
pubmed: 26960561
doi: 10.1007/s12094-016-1497-x
Dana, H. et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharmaceutica Sin. B 11, 1129–1147 (2021).
doi: 10.1016/j.apsb.2020.10.020
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S. & Katz, S. C. Assessing the future of solid tumor immunotherapy. Biomedicines 10, 655 (2022).
pubmed: 35327456
pmcid: 8945484
doi: 10.3390/biomedicines10030655
Herr, H. W. & Morales, A. History of Bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J. Urol. 179, 53–56 (2008).
pubmed: 17997439
doi: 10.1016/j.juro.2007.08.122
Garber, H. R., Mirza, A., Mittendorf, E. A. & Alatrash, G. Adoptive T-cell therapy for Leukemia. Mol. Cell Ther. 2, 25 (2014).
pubmed: 26056592
pmcid: 4452065
doi: 10.1186/2052-8426-2-25
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 363, 411–422 (2010).
Wojtukiewicz, M. Z. et al. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 40, 949–982 (2021).
pubmed: 34236546
pmcid: 8556173
doi: 10.1007/s10555-021-09976-0
Pandey, P. et al. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals 15, 335 (2022).
pubmed: 35337133
pmcid: 8952773
doi: 10.3390/ph15030335
Trager, M. H., Geskin, L. J. & Saenger, Y. M. Oncolytic viruses for the treatment of metastatic melanoma. Curr. Treat. Options Oncol. 21, 26 (2020).
pubmed: 32266483
doi: 10.1007/s11864-020-0718-2
Haitz, K., Khosravi, H., Lin, J. Y., Menge, T. & Nambudiri, V. E. Review of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanoma. J. Am. Acad. Dermatol. 83, 189–196 (2020).
pubmed: 32004650
doi: 10.1016/j.jaad.2020.01.039
Brown, C. E. et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072 (2015).
pubmed: 26059190
pmcid: 4632968
doi: 10.1158/1078-0432.CCR-15-0428
Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003–1010 (2020).
pubmed: 32437507
doi: 10.1001/jamaoncol.2020.1024
Assistance Publique—Hôpitaux de Paris. Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients. https://clinicaltrials.gov/study/NCT03294486 (2017).
DNAtrix, Inc. A Phase 1b, Randomized, Multi-Center, Open-Label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I). https://clinicaltrials.gov/study/NCT02197169 (2018).
Bristol-Myers Squibb. A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498). https://clinicaltrials.gov/study/NCT02617589 (2023).
Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935–1949 (2022).
pubmed: 35511454
pmcid: 9629431
doi: 10.1093/neuonc/noac116
Engeland, C. E., Heidbuechel, J. P. W., Araujo, R. P. & Jenner, A. L. Improving immunovirotherapies: the intersection of mathematical modelling and experiments. ImmunoInformatics 6, 100011 (2022).
doi: 10.1016/j.immuno.2022.100011
Totsch, S. K. et al. Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene 38, 6159–6171 (2019).
pubmed: 31289361
pmcid: 6771414
doi: 10.1038/s41388-019-0870-y
Jenner, A. L. et al. Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. iScience 25, 104395 (2022).
pubmed: 35637733
pmcid: 9142563
doi: 10.1016/j.isci.2022.104395
Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623, 157–166 (2023).
pubmed: 37853118
pmcid: 10620094
doi: 10.1038/s41586-023-06623-2
Eissa, I. R. et al. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers 10, 356 (2018).
pubmed: 30261620
pmcid: 6210336
doi: 10.3390/cancers10100356
Nassiri, F. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat. Med. 29, 1370–1378 (2023).
pubmed: 37188783
pmcid: 10287560
doi: 10.1038/s41591-023-02347-y
Jenner, A. L., Cassidy, T., Belaid, K., Bourgeois-Daigneault, M.-C. & Craig, M. In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. J. Immunother. Cancer 9, e001387 (2021).
pubmed: 33608375
pmcid: 7898884
doi: 10.1136/jitc-2020-001387
Le Boeuf, F. et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 18, 888–895 (2010).
pubmed: 20234341
pmcid: 2890112
doi: 10.1038/mt.2010.44
Bridle, B. W. et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther. 17, 1814–1821 (2009).
pubmed: 19603003
pmcid: 2835010
doi: 10.1038/mt.2009.154
Webb, E. S. et al. Immune checkpoint inhibitors in cancer therapy. J. Biomed. Res. 32, 317–326 (2018).
pubmed: 28866656
doi: 10.7555/JBR.31.20160168
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Louveau, A., Harris, T. H. & Kipnis, J. Revisiting the concept of CNS immune privilege. Trends Immunol. 36, 569–577 (2015).
pubmed: 26431936
pmcid: 4593064
doi: 10.1016/j.it.2015.08.006
Surendran, A. et al. Agent-based modelling reveals the role of the tumour microenvironment on the short-term success of combination temozolomide/immune checkpoint blockade to treat glioblastoma. J. Pharm. Exp. Ther. https://doi.org/10.1124/jpet.122.001571 (2023).
doi: 10.1124/jpet.122.001571
Falco, J. et al. In silico mathematical modelling for glioblastoma: a critical review and a patient-specific case. J. Clin. Med. 10, 2169 (2021).
pubmed: 34067871
pmcid: 8156762
doi: 10.3390/jcm10102169
Kronik, N., Kogan, Y., Vainstein, V. & Agur, Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol. Immunother. 57, 425–439 (2008).
pubmed: 17823798
doi: 10.1007/s00262-007-0387-z
Banerjee, S., Khajanchi, S. & Chaudhuri, S. A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure. PLoS ONE 10, e0123611 (2015).
pubmed: 25955428
pmcid: 4425651
doi: 10.1371/journal.pone.0123611
Khajanchi, S. The impact of immunotherapy on a glioma immune interaction model. Chaos Solitons Fractals 152, 111346 (2021).
doi: 10.1016/j.chaos.2021.111346
Khajanchi, S. & Nieto, J. J. Spatiotemporal dynamics of a glioma immune interaction model. Sci. Rep. 11, 22385 (2021).
pubmed: 34789751
pmcid: 8599515
doi: 10.1038/s41598-021-00985-1
Swanson, K. R., Rostomily, R. C. & Alvord, E. C. A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle. Br. J. Cancer 98, 113–119 (2008).
pubmed: 18059395
doi: 10.1038/sj.bjc.6604125
Eikenberry, S. E. et al. Virtual glioblastoma: growth, migration and treatment in a three-dimensional mathematical model. Cell Prolif. 42, 511–528 (2009).
pubmed: 19489983
pmcid: 6760820
doi: 10.1111/j.1365-2184.2009.00613.x
Storey, K. M. & Jackson, T. L. An agent-based model of combination oncolytic viral therapy and anti-PD-1 immunotherapy reveals the importance of spatial location when treating glioblastoma. Cancers 13, 5314 (2021).
pubmed: 34771476
pmcid: 8582495
doi: 10.3390/cancers13215314
de Montigny, J. et al. An in silico hybrid continuum-/agent-based procedure to modelling cancer development: Interrogating the interplay amongst glioma invasion, vascularity and necrosis. Methods 185, 94–104 (2021).
pubmed: 31981608
doi: 10.1016/j.ymeth.2020.01.006
Grimes, D. R., Jansen, M., Macauley, R. J., Scott, J. G. & Basanta, D. Evidence for hypoxia increasing the tempo of evolution in glioblastoma. Br. J. Cancer 123, 1562–1569 (2020).
pubmed: 32848201
pmcid: 7653934
doi: 10.1038/s41416-020-1021-5
Benítez, J. M., García-Mozos, L., Santos, A., Montáns, F. J. & Saucedo-Mora, L. A simple agent-based model to simulate 3D tumor-induced angiogenesis considering the evolution of the hypoxic conditions of the cells. Eng. Comput. 38, 4115–4133 (2022).
doi: 10.1007/s00366-022-01625-6
Malinzi, J., Basita, K. B., Padidar, S. & Adeola, H. A. Prospect for application of mathematical models in combination cancer treatments. Inform. Med. Unlocked 23, 100534 (2021).
doi: 10.1016/j.imu.2021.100534
Karimi, E. et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature 614, 555–563 (2023).
pubmed: 36725935
pmcid: 9931580
doi: 10.1038/s41586-022-05680-3
Omuro, A. et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 20, 674–686 (2018).
pubmed: 29106665
doi: 10.1093/neuonc/nox208
Duerinck, J. et al. Atim-38. Glitipni: a phase 1b clinical trial combining surgical resection with direct intracerebral injection of immune checkpoint inhibitors in patients with recurrent glioblastoma. Neuro-Oncol. 21, vi10 (2019).
pmcid: 6847104
doi: 10.1093/neuonc/noz175.037
Eisenbarth, D. & Wang, Y. A. Glioblastoma heterogeneity at single cell resolution. Oncogene 42, 2155–2165 (2023).
pubmed: 37277603
pmcid: 10913075
doi: 10.1038/s41388-023-02738-y
Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol. 8, 86 (2018).
pubmed: 29644214
pmcid: 5883082
doi: 10.3389/fonc.2018.00086
Ghaffarizadeh, A., Heiland, R., Friedman, S. H., Mumenthaler, S. M. & Macklin, P. PhysiCell: an open source physics-based cell simulator for 3-D multicellular systems. PLoS Comput. Biol. 14, e1005991 (2018).
pubmed: 29474446
pmcid: 5841829
doi: 10.1371/journal.pcbi.1005991
Ghaffarizadeh, A., Friedman, S. H. & Macklin, P. BioFVM: an efficient, parallelized diffusive transport solver for 3-D biological simulations. Bioinformatics 32, 1256–1258 (2016).
pubmed: 26656933
doi: 10.1093/bioinformatics/btv730
Bergman, D. et al. PhysiPKPD: a pharmacokinetics and pharmacodynamics module for PhysiCell. GigaByte 2022, gigabyte72 (2022).
pubmed: 36950142
pmcid: 10027063
Savić, M., Kurbalija, V., Balaz, I. & Ivanović, M. Heterogeneous tumour modeling using PhysiCell and its implications in precision medicine. In Cancer, Complexity, Computation (eds. Balaz, I. & Adamatzky, A.) 157–189 (Springer International Publishing, Cham, 2022).
Letort, G. et al. PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signalling. Bioinformatics 35, 1188–1196 (2019).
pubmed: 30169736
doi: 10.1093/bioinformatics/bty766
Gonçalves, I. G., Hormuth, D. A., Prabhakaran, S., Phillips, C. M. & García-Aznar, J. M. PhysiCOOL: a generalized framework for model calibration and optimization of modeLing projects. GigaByte 2023, gigabyte77 (2023).
pubmed: 36949818
pmcid: 10027115
Pietras, K. & Östman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324–1331 (2010).
pubmed: 20211171
doi: 10.1016/j.yexcr.2010.02.045
Wang, G. et al. Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities. Front. Immunol. 13, 964898 (2022).
pubmed: 35967394
pmcid: 9363573
doi: 10.3389/fimmu.2022.964898
Sadahiro, H. et al. Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. Cancer Res. 78, 3002–3013 (2018).
pubmed: 29531161
pmcid: 5984695
doi: 10.1158/0008-5472.CAN-17-2433
Ostermann, S. et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res 10, 3728–3736 (2004).
pubmed: 15173079
doi: 10.1158/1078-0432.CCR-03-0807
Strobel, H. et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines 7, 69 (2019).
pubmed: 31505812
pmcid: 6783999
doi: 10.3390/biomedicines7030069
Hotchkiss, K. M. & Sampson, J. H. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. J. Neurooncol. 151, 55–62 (2021).
pubmed: 32813186
doi: 10.1007/s11060-020-03598-2
Saha, D., Rabkin, S. D. & Martuza, R. L. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J. Immunother. Cancer 8, e000345 (2020).
pubmed: 32457126
pmcid: 7252967
doi: 10.1136/jitc-2019-000345
Storey, K. M., Lawler, S. E. & Jackson, T. L. Modeling oncolytic viral therapy, immune checkpoint inhibition, and the complex dynamics of innate and adaptive immunity in glioblastoma treatment. Front. Physiol. 11, 151 (2020).
pubmed: 32194436
pmcid: 7063118
doi: 10.3389/fphys.2020.00151
Aquilanti, E. & Brastianos, P. K. Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons. Neurosurgery 87, E281–E288 (2020).
pubmed: 32302389
pmcid: 7426188
doi: 10.1093/neuros/nyaa095
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A. & Sampson, J. H. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11, 504–514 (2015).
pubmed: 26260659
pmcid: 4782584
doi: 10.1038/nrneurol.2015.139
Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Van Roey, M. & Jooss, K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res. 14, 3933–3941 (2008).
pubmed: 18559615
doi: 10.1158/1078-0432.CCR-07-4732
Martinez-Quintanilla, J., He, D., Wakimoto, H., Alemany, R. & Shah, K. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol. Ther. 23, 108–118 (2015).
pubmed: 25352242
doi: 10.1038/mt.2014.204
Choi, I.-K. et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther. 17, 190–201 (2010).
pubmed: 19907500
doi: 10.1038/gt.2009.142
Zhang, W. et al. Efficacy of an oncolytic adenovirus driven by a chimeric promoter and armed with decorin against renal cell carcinoma. Hum. Gene Ther. 31, 651–663 (2020).
pubmed: 32216478
doi: 10.1089/hum.2019.352
Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827–1834 (2012).
pubmed: 23178246
pmcid: 3668784
doi: 10.1038/nm.3013
Han, J. et al. TGFβ treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Res. 75, 5273–5282 (2015).
pubmed: 26631269
pmcid: 4681611
doi: 10.1158/0008-5472.CAN-15-0894
The MathWorks Inc. MATLAB version: 23.2.0.2485118 (R2023b). (2023).